Urea cycle disorders are a group of rare congenital disorders caused by enzyme defects that affect the body's ability to remove ammonia from the bloodstream. Treatment of urea cycle disorders involves special diets low in protein, supplements such as carnitine and glycine, and medications to remove extra ammonia from the body. The market has witnessed significant growth due to the rising adoption of enzyme replacement therapies and increasing diagnosis rates of these rare genetic conditions.
Market Key Trends:
Growth Accelerated by Enzyme Replacement Therapies
The key trend fueling the growth of the U.S. Urea Cycle Disorders Treatment Market is the increasing adoption of enzyme replacement therapies. Enzyme replacement therapy helps replenish missing or malfunctioning enzymes in patients suffering from various genetic disorders. These therapies have transformed the treatment of urea cycle disorders by helping reduce toxic ammonia levels in the body. The U.S. FDA has approved drugs like Ravicti and Buphenyl that are used as adjunctive treatments along with dietary protein restriction and specialty formulas. The ability of these drugs to manage symptoms and prevent life-threatening hyperammonemic crises has significantly boosted their demand over the past few years.
Segment Analysis
The global U.S. Urea Cycle Disorders Treatment market is dominated by the drugs segment. This segment accounts for over 60% share of the total market owing to rising prevalence of genetic urea cycle disorders and availability of approved drug treatments for the same. The drugs sub-segment is further divided into Nitisinone, Sodium Benzoate, Sodium Phenylbutyrate, and Glycerol Phenylbutyrate. Among these, Sodium Phenylbutyrate holds the largest market share due to its wide usage for treatment of urea cycle disorders.
Key Takeaways
The Global U.S. Urea Cycle Disorders Treatment Market Size is expected to witness high growth over the forecast period. The global U.S. Urea Cycle Disorders Treatment Market is estimated to be valued at US$ 587.52 Mn in 2024 and is expected to exhibit a CAGR of 5.3% over the forecast period 2024 to 2031.
Regional analysis reveals that the North America region currently dominates the market and is expected to maintain its dominance through 2031. This is attributed to growing awareness levels about rare genetic disorders, strong reimbursement policies, and presence of leading manufacturers.
Key players operating in the U.S. Urea Cycle Disorders Treatment market are Kawasumi Laboratories Inc., Blood Purification Technologies Inc., AWAK Technologies Pte. Ltd, Triomed AB, Asahi Kasei Medical Vo. Ltd, US Kidney Research Corporation, Merit Medical Systems, NIPRO Medical Corporation, Fresenius SE & Co. KGaA.
Explore more information on this topic, Please visit -
https://www.insightprobing.com/u-s-urea-cycle-disorders-treatment-market-size-and-trends-analysis/
Explore more trending article related this topic -
https://www.pressreleasebulletin.com/refurbished-electronics-market-trends-size-and-share-analysis/
https://whotimes.com/stock-music-market-an-ever-evolving-industry/
Comments
0 comment